Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• AlisonMRIslamSWrightNAStem cells in cancer: instigators and propagators?J Cell Sci2010123pt 142357236820592182
   PubMed Web of Science ®Google Scholar
• ReyaTMorrisonSJClarkeMFWeissmanILStem cells, cancer, and cancer stem cellsNature2001414685910511111689955
   PubMed Web of Science ®Google Scholar
• MiragliaSGodfreyWYinAHA novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloningBlood19979012501350219389721
   PubMed Web of Science ®Google Scholar
• NadalROrtegaFGSalidoMCD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapyInt J Cancer2013133102398240723661576
   PubMed Web of Science ®Google Scholar
• WangWChenYDengJThe prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysisTumour Biol201435109769977524973892
   PubMedGoogle Scholar
• ChengBYangGJiangRCancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysisOncotarget2016740658626587527588469
   PubMedGoogle Scholar
• SuiYPJianXPMaLIPrognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: a meta-analysisMol Clin Oncol201641778226870362
   PubMedGoogle Scholar
• WenLChenXZYangKPrognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic reviewPLoS One201383e5915423533603
   PubMedGoogle Scholar
• IeniAGiuffreGAdamoVTuccariGPrognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomasAnticancer Res20113141315132021508381
   PubMedGoogle Scholar
• LinCHLiuCHWenCHKoPLChaiCYDifferential CD133 expression distinguishes malignant from benign papillary lesions of the breastVirchows Arch2015466217718425433813
   PubMedGoogle Scholar
• LiuQLiJGZhengXYJinFDongHTExpression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomasChin Med J (Engl)2009122222763276919951611
   PubMed Web of Science ®Google Scholar
• CurrieMJBeardsleyBEHarrisGCImmunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularityHum Pathol201344340241123036368
   PubMed Web of Science ®Google Scholar
• Di BonitoMCantileMCollinaFOverexpression of cell cycle progression inhibitor Geminin is associated with tumor stem-like phenotype of triple-negative breast cancerJ Breast Cancer201215216217122807933
   PubMed Web of Science ®Google Scholar
• AomatsuNYashiroMKashiwagiSCD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancerPLoS One201279e4586523049880
   PubMed Web of Science ®Google Scholar
• KapucuogluNBozkurtKKBaspinarSThe clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancerPathol Res Pract20152111074074726298632
   PubMedGoogle Scholar
• ZhaoPLuYJiangXLiXClinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinomaCancer Sci201110251107111121276138
   PubMed Web of Science ®Google Scholar
• MansourSFAtwaMMClinicopathological significance of CD133 and ALDH1 cancer stem cell marker expression in invasive ductal breast carcinomaAsian Pac J Cancer Prev201516177491749626625750
   PubMedGoogle Scholar
• KimSJKimYSJangEDSeoKJKimJSPrognostic impact and clinicopathological correlation of CD133 and ALDH1 expression in invasive breast cancerJ Breast Cancer201518434735526770241
   PubMed Web of Science ®Google Scholar
• LiuTJSunBCZhaoXLCD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancerOncogene201332554455322469978
   PubMed Web of Science ®Google Scholar
• LvXWangYSongYPangXLiHAssociation between ALDH1+/CD133+ stem-like cells and tumor angiogenesis in invasive ductal breast carcinomaOncol Lett20161131750175626998072
   PubMedGoogle Scholar
• HanZChenZZhengRChengZGongXWangDClinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesisWorld J Surg Oncol2015135625889325
   PubMed Web of Science ®Google Scholar
• MorrisonSJWandyczAMHemmatiHDWrightDEWeissmanILIdentification of a lineage of multipotent hematopoietic progenitorsDevelopment199712410192919399169840
   PubMedGoogle Scholar
• KummermehrJCTumour stem cells – the evidence and the ambiguityActa Oncol200140898198811845964
   PubMed Web of Science ®Google Scholar
• WangZWangQWangQWangYChenJPrognostic significance of CD24 and CD44 in breast cancer: a meta-analysisInt J Biol Markers Epub2016727
   Google Scholar
• WeiDPengJJGaoHZhangTTanYHuYHALDH1 expression and the prognosis of lung cancer: a systematic review and meta-analysisHeart Lung Circ201524878078825921687
   PubMed Web of Science ®Google Scholar
• SpangrudeGJHeimfeldSWeissmanILPurification and characterization of mouse hematopoietic stem cellsScience1988241486158622898810
   PubMedGoogle Scholar
• ZhangLGeCZhaoFNRBP2 overexpression increases the chemosensitivity of hepatocellular carcinoma cells via Akt signalingCancer Res201676237059707127634758
   PubMed Web of Science ®Google Scholar
• StanisavljevicLMyklebustMPLehSDahlOLGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancerActa Oncol201655121425143327435662
   PubMed Web of Science ®Google Scholar
• ZhouQChenASongHTaoJYangHZuoMPrognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysisInt J Clin Exp Med2015833080308826064196
   PubMed Web of Science ®Google Scholar
• MatsuiWHCancer stem cell signaling pathwaysMedicine (Baltimore)2016951 suppl 1S8S1927611937
   PubMed Web of Science ®Google Scholar
• PeterlinPGuillaumeTDelaunayJSimilarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patientsSemin Hematol201653321621727496314
   PubMedGoogle Scholar
• KellJThe addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemiaExpert Rev Anticancer Ther201616437738226942450
   PubMed Web of Science ®Google Scholar
• SansonePCeccarelliCBerishajMSelf-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancerNat Commun201671044226858125
   PubMed Web of Science ®Google Scholar
• ZhouLJiangYYanTThe prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literaturesBreast Cancer Res Treat2010122379580120571867
   PubMed Web of Science ®Google Scholar